Will Hormone Therapy Protect Your Brain? What the latest Alzheimer's Research Actually tells us

Two large research reviews came out this year, one in the Journal of Clinical Investigation, one in the journal Stroke, with basically the same headline: menopause might be the single biggest window we have for understanding a woman's future risk of Alzheimer's and vascular dementia. It's no surprise that the online wellness space followed with what it does best: turning "promising, nuanced, and complicated" into "start hormones asap or else you're doomed."

Obviously, that's a tempting read, we all want an easy out when it comes to dementia risk (my dad had dementia and it's my single biggest fear related to ageing), but it's far from what the research actually says.

What "everyone's" saying

You're already seeing this framed as: estrogen protects your brain, menopause depletes estrogen and negatively impacts your brain, so replacing the estrogen (via hormone therapy) is basically Alzheimer's prevention. It sounds like great news: a clear cause with an easy fix, and after decades of women being told "welcome to menopause, enjoy the ride" and not much else, I truly understand why we all want to desperately believe it to be true. It also lines up with something very real: women make up nearly two-thirds of Alzheimer's cases, and that gap isn't fully explained by simply living longer.

What is still missing from the story

Here's the nuance that gets lost that you need to be aware of. Women who use hormone therapy tend to be healthier, better resourced, and more consistently engaged with their own care to begin with, which makes it genuinely hard to know whether the therapy is protecting the brain, or whether the kind of woman who starts hormone therapy early already has fewer risk factors to begin with.

The numbers reveal how thin this margin is: one large analysis found it would take treating roughly 2,000 to 2,500 women for 18 years with hormone therapy to prevent a single Alzheimer's-related death. And the one gold-standard randomized trial we have (the Women's Health Initiative Memory Study) showed women who started hormone therapy after age 65 had double the risk of dementia compared to non hormone therapy users.

Current guidelines still don't recommend hormone therapy for dementia prevention in the general population. Not because the concept is wrong across the board, but because timing, formulation, and who actually benefits are still unclear.

What's actually happening

Here's what I think both papers actually reveal, and it's not "start hormones asap or your brain is toast." It's what many of us have been saying all along: that menopause is a real, whole-body neuro-endocrine event, not just the end of periods, not just hot flashes. The drop in estrogen affects inflammation, how efficiently your brain clears amyloid protein (a key factor in Alzheimer's and related dementia development), even how your brain cells produce energy. That's not a hormone problem you solve with a pill; it's a systems-level shift, and it's happening ten to twenty years before anyone would ever think to test for dementia, even with today's more sophisticated diagnostic tools. Which means if brain fog, forgotten words, or "I'm not as sharp as I was" have you wondering if you're losing your mind, you're not imagining it, and you're not being dramatic for wondering if it's all connected. You're just early to a conversation the research is still catching up to.

What to actually do with this information

Before you chase a prescription as brain insurance, I recommend the following:

Know your own risk profile. Early menopause, a hysterectomy with ovary removal before 45, and pregnancy complications like preeclampsia all show up in this research as real, individual risk markers, and none of them are routinely asked about at a standard checkup. This is relatively new and worth knowing: as of 2024, cardiology guidelines now formally recommend screening women for a history of adverse pregnancy outcomes specifically because they're linked to vascular brain injury that shows up decades later. If you had preeclampsia, gestational diabetes, or a preterm birth and no one has ever asked you about it since, that's not an oversight you want to tolerate. Make sure to bring it up yourself, whether that's with your doctor or with me - but it is part of my initial screening intake, so I usually get there first anyway ;).

Treat your cardiovascular and metabolic health as brain health, because it is. If I could shout this from the roof tops I would. A lot of us are scared by a future with dementia and often much less concerned with our creeping cholesterol or blood pressure. But in reality they are closely related. Blood pressure, cholesterol, blood sugar, and physical activity are estimated to account for up to 45% of modifiable Alzheimer's risk globally, and postmenopausal women specifically show greater vascular benefit from physical activity than younger women do, so this isn't a "should've started in your 20s and now you're too late to the party" kind of thing. It's more like "It's never too late to start moving and reap the widespread rewards of physical activity." That's not the exciting answer people want to hear, but it's honestly the one with the most evidence behind it.

Here's what that 45% actually breaks down into. No single factor decides your risk, and none of these are diagnostic on their own, but this is where the real, evidence-backed leverage is:

Modifiable risk factor	How much it raises your risk	Share of overall dementia risk
Hearing loss	90% higher	8.2%
Fewer years of education	60% higher	7.1%
Smoking	60% higher	5.2%
Depression	90% higher	3.9%
Social isolation	60% higher	3.5%
Traumatic brain injury	80% higher	3.4%
Air pollution exposure	10% higher	2.3%
Hypertension	60% higher	1.9%
Physical inactivity	40% higher	1.6%
Diabetes	50% higher	1.1%
Heavy alcohol use	20% higher	0.8%
Obesity	60% higher	0.7%

"How much it raises your risk" reflects the relative increase in risk for someone with that factor compared to someone without it, not your personal odds. "Share of overall dementia risk" is the bigger-picture number: how much of all dementia cases, across the population, trace back to that factor. Combined, these twelve factors account for an estimated 39.7% of dementia risk worldwide [7]. Newer research adding high LDL cholesterol and untreated vision loss to the list brings that combined estimate closer to the 45% figure above [6].

The pattern holds up across the newest cohorts too, including work on how these fractions shift by genetic risk and by race and ethnicity, and on how much vascular risk factors alone contribute depending on when in life they show up [8,9,10]. None of this is about doing everything perfectly. It's about knowing where the actual leverage is instead of guessing.

If you're considering hormone therapy, have that conversation on its actual known and well established merits. Symptom relief (very important, especially when this is a meaningful barrier to you actually exercising to begin with), bone health, your individual history, and ideally alongside someone who has the time to walk through the timing and trade-offs with you. Not as a blanket "for my brain" decision.

Why this matters

The riskiest default reactions here are the ones I see everywhere with increasingly simplified and polarized messaging in the women's health space: dismiss menopause as "just" hot flashes and a natural transition to power through, or oversell hormones as the fix for everything and elixir of youth. Both let you off the hook from the actual work of getting clear about your medical history, asking better questions, and building the foundations that hold up over decades. The women who I see navigating this transition with confidence aren't the ones who found the magic prescription, the fewest symptoms, or the lowest risk profile. They're the ones who got curious about their own health and risks early enough to do something useful with it.

That's the whole premise of the Maintain & Prevent work I do with patients once we've gotten them feeling more like themselves. This is the core of the conversation, backed by solid, reliable evidence, minus the hype.

If you want to a risk reduction strategy you have to actually map out what your personal risk profile looks like, reproductive history, cardiovascular markers, the whole picture, and that comes from a thorough conversation, not a prescription pad.

References

1. Mosconi L. Women's midlife: the front line of Alzheimer prevention. J Clin Invest. 2026;136(6):e199832. doi:10.1172/JCI199832.

2. Pikula A, et al. Midlife as the critical window for women's stroke and dementia prevention: pivotal advances and implementation priorities. Stroke. 2026;57(6):1810-1820. doi:10.1161/STROKEAHA.125.051747.

3. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. doi:10.1001/jama.2017.11217.

4. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study, a randomized controlled trial. JAMA. 2003;289(20):2651-2662.

5. Frisoni GB, Hansson O, Nichols E, et al. New landscape of the diagnosis of Alzheimer's disease. Lancet. 2025;406(10510). doi:10.1016/S0140-6736(25)01294-2.

6. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0.

7. Reuben DB, Kremen S, Maust DT. Dementia prevention and treatment: a narrative review. JAMA Intern Med. 2024;184(5):563-572. doi:10.1001/jamainternmed.2023.8522.

8. Park SY, Setiawan VW, Crimmins EM, et al. Racial and ethnic differences in the population-attributable fractions of Alzheimer disease and related dementias. Neurology. 2024;102(3):e208116. doi:10.1212/WNL.0000000000208116.

9. Tian F, Zhao J, Chen L, Wei S, Lin H. Prioritizing modifiable risk factors for dementia prevention across the spectrum of genetic susceptibility: a prospective cohort study. Ann Neurol. 2025;98:1210-1221. doi:10.1002/ana.78060.

10. Smith JR, Pike JR, Gottesman RF, et al. Contribution of modifiable midlife and late-life vascular risk factors to incident dementia. JAMA Neurol. 2025;82(7):644-654. doi:10.1001/jamaneurol.2025.1495.